1-(4-bromobutoxy)-3-(trifluoromethyl)-benzene | 70743-66-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-bromobutoxy)-3-(trifluoromethyl)-benzene
• 英文别名: 1-bromo-4-(3-trifluoromethylphenoxy)butane；4-(m-(trifluoromethyl)phenoxy)-1-bromobutane；1-(4-Bromobutoxy)-3-(trifluoromethyl)benzene
• CAS: 70743-66-7
• 化学式: C₁₁H₁₂BrF₃O
• mdl: MFCD11213831
• 分子量: 297.115
• InChiKey: PMAFRLNIEQFVSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(4-bromobutoxy)-3-(trifluoromethyl)-benzene 在 potassium tert-butylate 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 48.0h， 生成 2-benzoyl-5-(3-(trifluoromethyl)phenoxy)pentanenitrile
  参考文献：
  名称：

  Reactions of 4-substituted 1-[(difluoromethyl)sulfinyl]polyfluorobenzenes with phenolate anion

  摘要：

  The reactions of 4-substituted-polyfluorinated-[(difluoromethyl)sulfinyl]benzenes ([4-X-C6F4S(O)CHF2 [X = H, CF3 and C6F5S(O)]) with phenolate anion in benzene, Et2O and CH3CN have been investigated. The reactions of the substrate (X = H, CF3) and sodium phenolate in equal amounts resulted in the formation of mixtures of the starting compound, 2-phenoxyderivative and disubstituted products. The two-fold amount of the phenolate afforded the 2,6-disubstituted products for X = H in MeCN and for X = CF3 in Et2O. At the same time, 4-CF3-C6F4S(O)CHF2 in CH3CN gave a mixture of the 2,6- and 2,5-bis(phenoxy) derivatives. Quantum chemical calculations have been performed to explain this phenomenon. For X = C 6 F 5 S(0) in MeCN, the reaction was accompanied by sulfinyl moiety ipso-substitution.[GRAPHICS].

  DOI：

  10.24820/ark.5550190.p011.262
• 作为产物：
  描述：

  1,4-二溴丁烷 、 间三氟甲基苯酚 在 potassium carbonate 作用下， 以 乙醇 为溶剂， 反应 17.0h， 以62%的产率得到1-(4-bromobutoxy)-3-(trifluoromethyl)-benzene
  参考文献：
  名称：

  钴（I）催化的未活化烷基溴化物和氯化物的硼氢化作用。

  摘要：

  在温和的反应条件下，已开发出钴配合物催化的多种烷基卤化物与二硼试剂（B2pin2或B2neop2）的硼化反应，这证明了钴与烷基亲电试剂的首次交联。该协议允许从烷基卤化物（包括烷基氯化物）中获取烷基硼酸酯，而烷基卤化物很少用作偶联伙伴。机理研究表明，烷基中间体可能参与了该钴介导的催化循环。

  DOI：

  10.1021/acs.orglett.0c00038

文献信息

• Design of PAP-1, a Selective Small Molecule Kv1.3 Blocker, for the Suppression of Effector Memory T Cells in Autoimmune Diseases
  作者：Alexander Schmitz、Ananthakrishnan Sankaranarayanan、Philippe Azam、Kristina Schmidt-Lassen、Daniel Homerick、Wolfram Hänsel、Heike Wulff

  DOI：10.1124/mol.105.015669

  日期：2005.11

  The lymphocyte K+ channel Kv1.3 constitutes an attractive pharmacological target for the selective suppression of terminally differentiated effector memory T (TEM) cells in T cell-mediated autoimmune diseases, such as multiple sclerosis and type 1 diabetes. Unfortunately, none of the existing small-molecule Kv1.3 blockers is selective, and many of them, such as correolide, 4-phenyl-4-[3-(methoxyphenyl)-3-oxo-2-azapropyl]cyclohexanone, and our own compound Psora-4 inhibit the cardiac K+ channel Kv1.5. By further exploring the structure-activity relationship around Psora-4 through a combination of traditional medicinal chemistry and whole-cell patch-clamp, we identified a series of new phenoxyalkoxypsoralens that exhibit 2- to 50-fold selectivity for Kv1.3 over Kv1.5, depending on their exact substitution pattern. The most potent and “drug-like” compound of this series, 5-(4-phenoxybutoxy)psoralen (PAP-1), blocks Kv1.3 in a use-dependent manner, with a Hill coefficient of 2 and an EC50 of 2 nM, by preferentially binding to the C-type inactivated state of the channel. PAP-1 is 23-fold selective over Kv1.5, 33- to 125-fold selective over other Kv1-family channels, and 500- to 7500-fold selective over Kv2.1, Kv3.1, Kv3.2, Kv4.2, HERG, calcium-activated K+ channels, Na+,Ca2+, and Cl- channels. PAP-1 does not exhibit cytotoxic or phototoxic effects, is negative in the Ames test, and affects cytochrome P450-dependent enzymes only at micromolar concentrations. PAP-1 potently inhibits the proliferation of human TEM cells and suppresses delayed type hypersensitivity, a TEM cell-mediated reaction, in rats. PAP-1 and several of its derivatives therefore constitute excellent new tools to further explore Kv1.3 as a target for immunosuppression and could potentially be developed into orally available immunomodulators.

  淋巴细胞K+通道Kv1.3是选择性抑制T细胞介导的自身免疫性疾病（如多发性硬化症和1型糖尿病）中终末分化效应记忆T（TEM）细胞的有吸引力的药理学靶点。不幸的是，目前存在的所有小分子Kv1.3阻断剂均不具备选择性，其中许多如柯里奥利德、4-苯基-4-[3-(甲氧苯基)-3-酮-2-氮杂丙基]环己酮以及我们自己的化合物Psora-4均可抑制心脏K+通道Kv1.5。通过结合传统药物化学和全细胞膜片钳技术进一步探索Psora-4的构效关系，我们鉴定了一系列新的苯氧烷氧基补骨脂素，它们对Kv1.3的选择性比Kv1.5高2至50倍，具体取决于其取代模式。这一系列化合物中，最具有强效和“类药物”性质的化合物为5-(4-苯氧基丁氧基)补骨脂素（PAP-1），它以使用依赖性方式阻断Kv1.3，Hill系数为2，EC50为2 nM，通过优先结合通道的C型失活态。PAP-1对Kv1.5的选择性为23倍，对其他Kv1家族通道的选择性为33至125倍，对Kv2.1、Kv3.1、Kv3.2、Kv4.2、HERG、钙激活K+通道、Na+、Ca2+及Cl-通道的选择性为500至7000倍。PAP-1无细胞毒性或光毒性，Ames试验呈阴性，对细胞色素P450依赖性酶的影响仅在微摩尔浓度下显现。PAP-1能强效抑制人TEM细胞的增殖并抑制大鼠中的迟发型超敏反应（一种TEM细胞介导的反应）。因此，PAP-1及其若干衍生物构成了探索Kv1.3作为免疫抑制靶点的新工具，并有可能开发成口服可用的免疫调节剂。
• 2-substituted piperidine analogs and their use as subtype-selective NMDA
  申请人：Warner-Lambert Company

  公开号：US06124317A1

  公开（公告）日：2000-09-26

  Novel 2-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using 2-substituted piperidine analogs as selectively active antagonists of N-methyl-D-aspartatc (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, anxiety, convulsions, amioglycoside antibiotics-induced hearing loss, migraine headaches, chronic pain, glaucoma, CMV retinitis, psychosis, urinary incontinence, opioid tolerance or withdrawal, or neurodegenerative disorders, such as lathyrism, Alzheimer's Disease, Parkinsonism and Huntington's Disease are described.

  小说中描述了2-取代哌啶类似物、含有这些类似物的药物组合物，以及使用2-取代哌啶类似物作为选择性活性拮抗剂的方法，用于治疗中风、脑缺血、中枢神经系统创伤、低血糖、焦虑、抽搐、氨基糖苷类抗生素引起的听力损失、偏头痛、慢性疼痛、青光眼、巨细胞病毒性视网膜炎、精神病、尿失禁、阿片类耐受性或戒断症状，或神经退行性疾病，如拉锥病、阿尔茨海默病、帕金森病和亨廷顿病。
• Angiogenesis inhibiting thiadiazolyl pyridazine derivatives
  申请人：Janssen Pharmaceutica N.V.

  公开号：US06265407B1

  公开（公告）日：2001-07-24

  This invention concerns compounds of formula the N-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein R1 is hydrogen, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, mono- or di(C1-6alkyl)amino, Ar1, Ar1—NH—, C3-6cycloalkyl, hydroxymethyl or benzyloxymethyl; R2 and R3 are hydrogen, or taken together may form a bivalent radical of formula —CH═CH—CH═CH—; R4, R5 and R6 are each independently selected from hydrogen, halo, C1-6alkyl, C1-6alkyloxy, trifluoromethyl, nitro, amino, cyano, azido, C1-6alkyloxyC1-6alkyl, C1-6alkylthio, C1-6alkyloxycarbonyl or Het1; or when R4 and R5 are adjacent to each other they may be taken together to form a radical of formula —CH═CH—CH═CH—; A is a bivalent radical of formula NR7, NR7—Alk1—X—, NR7—Alk1—X—Alk2—, O—Alk1—X—, O—Alk1—X—Alk2— or S—Alk1—X—; wherein X is a direct bond, —O—, —S—, C═O, —NR8— or Het2; R7 is hydrogen, C1-6alkyl or Ar2methyl; R8 is hydrogen, C1-6alkyl or Ar2methyl; Alk1 is C1-6alkanediyl; Alk2 is C1-4alkanediyl; Ar1 and Ar2 are optionally substituted phenyl; phenyl; Het1 and Het2 are optionally substituted heterocycles; having angiogenesis inhibiting activity; their preparation, compositions containing them and their use as a medicine.

  这项发明涉及公式N-氧化物形式的化合物，其药学上可接受的酸盐和立体化学异构体形式，其中R1为氢、C1-6烷基、C1-6烷氧基、C1-6烷硫基、氨基、单或双(C1-6烷基)氨基、Ar1、Ar1—NH—、C3-6环烷基、羟甲基或苄氧甲基；R2和R3为氢，或者合并在一起可以形成公式—CH═CH—CH═CH—的二价基团；R4、R5和R6分别独立地选自氢、卤素、C1-6烷基、C1-6烷氧基、三氟甲基、硝基、氨基、氰基、叠氮基、C1-6烷氧基C1-6烷基、C1-6烷硫基、C1-6烷氧羰基或Het1；或者当R4和R5相邻时，它们可以合并在一起形成公式—CH═CH—CH═CH—的基团；A为公式NR7、NR7—Alk1—X—、NR7—Alk1—X—Alk2—、O—Alk1—X—、O—Alk1—X—Alk2—或S—Alk1—X—的二价基团；其中X为直接键、—O—、—S—、C═O、—NR8—或Het2；R7为氢、C1-6烷基或Ar2甲基；R8为氢、C1-6烷基或Ar2甲基；Alk1为C1-6烷二基；Alk2为C1-4烷二基；Ar1和Ar2为可选取代的苯基；苯基；Het1和Het2为可选取代的杂环；具有抑制血管生成活性；它们的制备、含有它们的组合物以及它们作为药物的用途。
• Phenalkoxyalkyl- and phenoxyalkyl-substituted oxiranecarboxylic acids,
  申请人：Byk Gulden Lomberg Chemische Fabrik GmbH

  公开号：US04337267A1

  公开（公告）日：1982-06-29

  Phenalkoxyalky- and phenoxyalkyl-substituted oxiranecarboxylic acids of the formula ##STR1## wherein R.sup.1 denotes a hydrogen atom (--H), a halogen atom, a lower alkyl group, a lower alkoxy group, a nitro group or a trifluoromethyl group, R.sup.2 has one of the meanings of R.sup.1, R.sup.3 denotes a hydrogen atom (--H) or a lower alkyl group, Y denotes --O--(CH.sub.2).sub.m --, m denotes O or an integer from 1 to 4, and n denotes an integer from 2 to 8, with the proviso that the sum of m and n is an integer from 2 to 8, and the salts of the acids are new compounds. They display a hypoglycaemic action in warm-blooded animals. Processes for the preparation of the new compounds and of the intermediate products required for their preparation are described.

  公式为##STR1##的苯基氧丙基和苯氧丙基取代的环氧丙酸，其中R1表示氢原子（-H），卤素原子，低碳基，低烷氧基，硝基或三氟甲基基团，R2具有R1的一种含义，R3表示氢原子（-H）或低碳基，Y表示- O-（CH2）m-，m表示O或1至4的整数，n表示2至8的整数，但m和n的和是2至8的整数，酸盐是新化合物。它们在温血动物中显示出降血糖作用。描述了制备新化合物和制备所需中间产物的过程。
• Hydrierte 1-Phenoxyalkylpyridin-3-carbonsäureverbindungen
  申请人：CIBA-GEIGY AG

  公开号：EP0252876A1

  公开（公告）日：1988-01-13

  Die Erfindung betrifft neue hydrierte 1-Phenoxyalkylpyri- din-3-carbonsäureverbindungen der Formel worin R 1 Niederalkoxycarbonyl, Carbamyl, N-Niederalkylcarbamyl, N,N-Diniederalkylcarbamyl oder gegebenenfalls acyliertes Hydroxymethyl bedeutet, R 2 Wasserstoff, eine gegebenenfalls verätherte oder acylierte Hydroxygruppe oder eine gegebenenfalls acylierte Aminogruppe darstellt, alk Niederalkylen bedeutet, der Ring A unsubstituiert oder ein- oder mehrfach durch Hydroxy, Niederalkoxy, Niederalkanoyloxy, Cyano, Halogen, Niederalkyl und/oder Trifluormethyl substituiert ist und die gestrichelte Linie zum Ausdruck bringen soll, dass eine Einfach- oder eine Doppelbindung vorliegt, und ihre Tautomeren und/oder Salze. Diese Verbindungen können als pharmazeutische Wirkstoffe verwendet werden und sind in an sich bekannter Weise herstellbar.

  本发明涉及新的氢化 1-苯氧基烷基吡啶-3-羧酸化合物，其式为 其中 R 1 代表低级烷氧基羰基、氨基甲酰基、N-低级烷基氨基甲酰基、N,N-二低级烷基氨基甲酰基或任选酰化的羟甲基，R 2 代表氢、任选醚化或酰化的羟基或任选酰化的氨基，烷代表低级亚烷基、环 A 未被羟基、低级烷氧基、低级烷酰氧基、氰基、卤素、低级烷基和/或三氟甲基取代，或被羟基、低级烷氧基、低级烷酰氧基、氰基、卤素、低级烷基和/或三氟甲基单取代或多取代。这些化合物可用作活性药物成分，并可以已知的方式制备。